Drugs / Adacel Quadra
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04300192 | Jan 2021 → Jan 2023 | diphtheria, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adacel Quadra | “Group 1: Adacel Quadra vaccine” NCT04300192 ↗ |
| Known as | Adacel-Polio, Adacel Quadra | “Adacel®-Polio, Adacel Quadra®” NCT04300192 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04300192 ↗ |